In compliance with section 17(b) of the Securities Act, we are disclosing that Pasithea Therapeutics, Corp. is a client of TraDigital Marketing Group, Inc., and Pasithea Therapeutics, Corp. has an agreement in place to compensate TraDigital Marketing Group, Inc. a cash fee of three hundred ninety-four thousand USD for investor relations services, and a one-time stock fee of 150,000 shares of common stock, restricted under Rule 144, for TraDigital Marketing Group, Inc., investor awareness and digital marketing services. The stock is eligible for sale on 03/17/2022. Although we are not obligated to sell our shares, for the purpose of this disclosure, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/17/2022.
Investor awareness and investor relations services and programs are designed to help small-cap companies communicate their investment characteristics. TraDigital Marketing Group, Inc., investor awareness and advisory services include multimedia marketing and other awareness services.